Has Gabrielle Union confirmed taking HRT for perimenopause?

Union has confirmed experiencing perimenopause symptoms and receiving medical care for them. She has not publicly named specific medications, dosages, or whether her treatment includes hormone replacement therapy specifically. The clinical protocols discussed in this article are standard-of-care projections, not confirmed details of her personal regimen.

Is HRT safe for women with a history of adenomyosis?

Low-dose transdermal estradiol with micronized progesterone is generally considered safe for women with a history of adenomyosis, though monitoring for symptom recurrence is recommended. Adenomyosis is estrogen-responsive, so the lowest effective dose is preferred. Clinical data on this specific population remains limited, and treatment should be individualized with a gynecologist or reproductive endocrinologist familiar with the patient's history.

Does prior IVF affect HRT safety later in life?

Current guidelines do not specifically modify HRT recommendations based on prior IVF history. The cumulative hormonal exposure from multiple IVF cycles is a theoretical consideration, but no large-scale studies have demonstrated increased MHT risks specifically attributable to prior fertility treatment. The standard approach is to assess current risk factors (age, time since menopause, cardiovascular and breast cancer risk) when making prescribing decisions.

Why are Black women less likely to receive HRT?

Research published in *Menopause* and other journals has documented racial disparities in MHT prescribing. Contributing factors include provider bias, differences in symptom reporting patterns, historical mistrust of medical institutions, and unequal access to menopause-specialized care. These disparities persist even when symptom severity is comparable across racial groups.

What Gabrielle Union's Reported Protocol Might Look Like Clinically

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Gabrielle Union Has Actually Said

Gabrielle Union has been unusually candid about her reproductive health journey. In her 2017 memoir We're Going to Need More Wine and in a 2018 interview with People magazine, she described years of failed IVF cycles, multiple miscarriages, and an adenomyosis diagnosis. She confirmed undergoing "eight or nine" IVF attempts before her daughter Kaavia was born via surrogate in November 2018.

In subsequent interviews, including a 2022 conversation on the I Weigh podcast and remarks shared on her Instagram, Union has discussed experiencing perimenopause symptoms in her late 40s. She has described hot flashes, sleep disruption, and mood shifts. She has confirmed receiving medical care for these symptoms, though she has not publicly named specific medications or dosages.

The HealthRX Medical Team wants to be clear: Union has confirmed fertility hormone use (IVF protocols) and confirmed perimenopause symptom management under medical supervision. The specific drugs and doses discussed below are clinical projections based on standard-of-care protocols, not confirmed details of her personal prescriptions.

At a glance

Confirmed: Multiple IVF cycles, adenomyosis diagnosis, perimenopause symptoms under medical care
Not publicly confirmed: Specific HRT drug names, dosages, or current regimen details
Drug families involved: Gonadotropins (fertility), estrogen/progesterone (perimenopause management)
Clinical relevance: Union's timeline spans both assisted reproduction and menopausal transition, two distinct but hormonally connected treatment phases

Phase One: The IVF Hormone Protocol

Union's confirmed IVF history means she received controlled ovarian hyperstimulation, the hormonal backbone of every IVF cycle. Standard protocols involve injectable gonadotropins such as follicle-stimulating hormone (FSH) and sometimes luteinizing hormone (LH), administered daily for 8 to 14 days.

A typical cycle for a woman in her mid-to-late 30s (Union was approximately 35 to 44 during her IVF years) would include:

Ovarian suppression using a GnRH agonist (leuprolide) or GnRH antagonist (cetrorelix, ganirelix) to prevent premature ovulation. Stimulation with recombinant FSH (follitropin alfa or beta) at doses often starting around 225 to 300 IU daily, adjusted based on follicular response monitored via ultrasound. Trigger shot with hCG (human chorionic gonadotropin) or a GnRH agonist trigger once follicles reach maturity. Luteal support with progesterone, typically intramuscular or vaginal, continuing through early pregnancy confirmation.

Each failed cycle means repeating this hormonal exposure. Eight or nine cycles represents a substantial cumulative dose of exogenous hormones, and the emotional and physical toll Union has described publicly aligns with what reproductive endocrinologists observe in patients undergoing repeated stimulation. A 2019 Cochrane review confirmed that while short-term safety of gonadotropins is well-established, long-term data on repeated cycles remains an active area of study, particularly regarding ovarian reserve depletion.

Phase Two: Perimenopause and Hormone Therapy

Union's public discussion of perimenopause symptoms in her late 40s places her squarely within the typical age window. The Study of Women's Health Across the Nation (SWAN) established that the menopausal transition begins on average at age 47, with vasomotor symptoms (hot flashes, night sweats) affecting up to 80% of women.

For a woman with Union's profile (mid-to-late 40s, history of adenomyosis, perimenopausal vasomotor symptoms), the HealthRX Medical Team would expect a prescribing discussion to include:

Estradiol therapy. Transdermal estradiol patches (0.025 to 0.05 mg/day) or low-dose oral estradiol (0.5 to 1.0 mg/day) represent first-line treatment for vasomotor symptoms per 2022 North American Menopause Society (NAMS) guidelines. The transdermal route carries a lower venous thromboembolism risk compared to oral formulations, a consideration the WHI follow-up analyses have reinforced.

Micronized progesterone. Because Union has a uterus (her daughter was born via surrogate, not hysterectomy), any estrogen therapy requires progestogen co-administration to protect the endometrium from hyperplasia. Micronized progesterone 100 to 200 mg nightly is the standard pairing, and NAMS data shows it may also improve sleep quality, addressing another symptom Union has described publicly.

Adenomyosis consideration. This is where Union's case becomes clinically distinctive. Adenomyosis, a condition where endometrial tissue grows into the uterine muscle wall, is estrogen-responsive. A clinician managing her perimenopause would need to balance symptom relief against the theoretical risk of reactivating adenomyosis-related pain or bleeding with systemic estrogen. The 2023 ESHRE guidelines note that lower-dose estrogen formulations are generally preferred in this context, with close monitoring for symptom recurrence.

The HealthRX Medical Team Clinical Framework

The HealthRX Medical Team identifies three clinical tensions in a case matching Union's public profile:

1. Cumulative hormonal exposure. A woman who underwent eight or more IVF cycles before age 45 and then transitions to menopausal hormone therapy has a longer total duration of exogenous hormone exposure than the average MHT patient. Current Endocrine Society guidelines do not specifically adjust MHT recommendations based on prior IVF history, but a cautious prescriber would likely start at the lowest effective dose and reassess annually.

2. Adenomyosis and estrogen. Post-menopause typically resolves adenomyosis as endogenous estrogen drops. Reintroducing estrogen via MHT could, in theory, reactivate symptoms. The clinical literature here is limited. A 2020 case series in the Journal of Minimally Invasive Gynecology reported that low-dose transdermal estradiol did not reactivate adenomyosis in most patients, but sample sizes were small. This is a clinical gray zone requiring individualized monitoring.

3. Timing hypothesis. The WHI reanalysis and subsequent NAMS position statements support initiating MHT within 10 years of menopause onset or before age 60 for the most favorable risk-benefit ratio. Union, currently 53, falls within the window where initiation (if it hasn't already occurred) would still align with guideline-supported timing. Delaying beyond this window shifts the risk calculus, particularly for cardiovascular outcomes.

What This Case Illustrates About Perimenopause Care

Union's public willingness to discuss perimenopause is notable because it challenges a persistent silence. A 2023 survey published in Menopause found that only 40% of perimenopausal women discussed their symptoms with a healthcare provider, and Black women reported lower rates of MHT prescribing despite equal or higher vasomotor symptom burden. The same data showed Black women were 50% less likely to receive HRT prescriptions compared to white women, even after controlling for symptom severity.

The HealthRX Medical Team notes that Union's platform reaches millions of Black women who are statistically underserved in menopausal care. Her openness about seeking treatment does not constitute medical advice, but it does contribute to normalizing a conversation that has measurable gaps in healthcare access. The Office on Women's Health lists perimenopause education as a priority area precisely because undertreated symptoms affect quality of life, work productivity, and long-term bone and cardiovascular health.

Side Effect Profile Worth Knowing

For any woman considering the type of MHT protocol described above, the HealthRX Medical Team flags these evidence-based side effects:

Common (first 1 to 3 months): breast tenderness, spotting or irregular bleeding, bloating, headaches. These typically resolve with continued use or dose adjustment.

Monitored risks: The WHI data established a small absolute increase in breast cancer risk with combined estrogen-progestin therapy (approximately 8 additional cases per 10,000 women per year after 5+ years of use). Estrogen alone did not show this increase. Venous thromboembolism risk is elevated with oral (not transdermal) estrogen.

Contraindications: Active breast cancer, undiagnosed vaginal bleeding, active liver disease, history of blood clots with hormonal therapy. A thorough personal and family history is required before initiation.

Frequently asked questions

›